Prenetics Global Limited (NASDAQ:PRE - Free Report) - Cantor Fitzgerald issued their FY2026 earnings estimates for Prenetics Global in a research report issued on Friday, June 13th. Cantor Fitzgerald analyst R. Osborn forecasts that the company will post earnings of ($1.01) per share for the year. The consensus estimate for Prenetics Global's current full-year earnings is ($3.30) per share.
Prenetics Global (NASDAQ:PRE - Get Free Report) last issued its quarterly earnings data on Thursday, June 12th. The company reported ($0.80) earnings per share (EPS) for the quarter. The business had revenue of $17.31 million during the quarter. Prenetics Global had a negative return on equity of 28.07% and a negative net margin of 115.91%.
Prenetics Global Stock Up 23.3%
Shares of NASDAQ:PRE traded up $1.75 on Monday, reaching $9.26. The company had a trading volume of 380,483 shares, compared to its average volume of 20,617. The stock has a market capitalization of $112.97 million, a P/E ratio of -2.32 and a beta of 0.17. The stock has a 50-day moving average price of $6.59 and a 200 day moving average price of $5.58. Prenetics Global has a twelve month low of $3.09 and a twelve month high of $11.99.
Institutional Inflows and Outflows
An institutional investor recently bought a new position in Prenetics Global stock. Quinn Opportunity Partners LLC bought a new position in shares of Prenetics Global Limited (NASDAQ:PRE - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 12,339 shares of the company's stock, valued at approximately $72,000. Quinn Opportunity Partners LLC owned 0.10% of Prenetics Global as of its most recent SEC filing. 25.01% of the stock is currently owned by institutional investors.
About Prenetics Global
(
Get Free Report)
Prenetics Global Limited, a genomics-driven health sciences company, engages in revolutionizing prevention, early detection, and treatment. It offers CircleDNA, a prevention arm that uses whole exome sequencing to offer comprehensive consumer DNA test. The company also, through its joint venture, Insighta, engages in pioneering multi-cancer early detection technologies.
Further Reading
Before you consider Prenetics Global, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Prenetics Global wasn't on the list.
While Prenetics Global currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
